Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05901467 · ClinicalTrials.gov registry record · Phase 1
Recall by Genotype: Neuropeptide Stimulation
A Phase 1 study, sponsored by Stephanie B. Seminara, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05901467: Clinical Trial Phase 1 study, sponsored by Stephanie B. Seminara, MD.
NCT05901467 is a Phase 1 study that was terminated before completion, run by Stephanie B. Seminara, MD. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05901467, a Phase 1 study, was terminated before completion, sponsored by Stephanie B. Seminara, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.
Primary Outcome
Average amplitude of LH pulses at baseline
Interventions
- DRUG kisspeptin 112-121
- DRUG GnRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 1 |
Why NCT05901467 stopped before completion
NCT05901467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.
NCT05901467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05901467 about?
NCT05901467 is a clinical study titled "Recall by Genotype: Neuropeptide Stimulation". The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.
What is the current status of trial NCT05901467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-20. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT05901467?
The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).
Who is sponsoring clinical trial NCT05901467?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05901467's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI